Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glenmark’s Novel Molecule For Neuropathic Pain, Osteoarthritis To Enter Phase I Trials

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Indian drug maker Glenmark Pharmaceuticals' lead molecule for neuropathic pain, osteoarthritis and other inflammatory pain will enter Phase I trials shortly, the company announced, after filing for Phase I approval with European regulatory authorities

You may also be interested in...



Glenmark Sets Up Clinical R&D Unit At Oxford As Drug Pipeline Swells

MUMBAI - Glenmark Pharmaceuticals, one of India's fastest growing research-based drug companies, has set up a new clinical research and development outfit at Oxford Science and Business Park in the United Kingdom

Glenmark Sets Up Clinical R&D Unit At Oxford As Drug Pipeline Swells

MUMBAI - Glenmark Pharmaceuticals, one of India's fastest growing research-based drug companies, has set up a new clinical research and development outfit at Oxford Science and Business Park in the United Kingdom

Almirall’s Loss of Aclidinium Could Be Glenmark’s Gain

MUMBAI - Hopes for oglemilast, Glenmark's chronic obstructive pulmonary disease candidate being developed by U.S.-based Forest Laboratories brightened after rival experimental drug aclidinium - also licensed by Forest - showed disappointing results in Phase III studies

Related Content

UsernamePublicRestriction

Register

LL1134361

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel